Mirati Therapeutics And Aadi Bioscience Partner To Evaluate The Combination Of Adagrasib With Nab-sirolimus In Patients With Advanced Non-Small Cell Lung Cancer And Other Solid Tumors With A KRAS[G12C] Mutation
Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, and Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial stage biopharmaceutical company focused on developing and commercializing
Aadi Bioscience Announces $72.5M Private Placement Equity Financing Of 3,373,526 Shares At A Price Of $12.50/Share
LOS ANGELES, Sept. 22, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in
Aadi Bioscience: Q2 Earnings Insights
Aadi Bioscience (NASDAQ:AADI) reported its Q2 earnings results on Wednesday, August 10, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings Scheduled For August 10, 2022
Companies Reporting Before The Bell
• Wix.com (NASDAQ:WIX) is estimated to report earnings for its second quarter.
Aadi Bioscience: Q1 Earnings Insights
Aadi Bioscience (NASDAQ:AADI) reported its Q1 earnings results on Thursday, May 12, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings
Aadi Bioscience beat estimated earnings by 7.04%, reporting an EPS of $-0.66 versus an estimate of $-0.71.
Aadi Bioscience Announces Collaborations With Next Generation Sequencing Leaders
Company enters into collaborations with leading next generation sequencing (NGS) companies to facilitate trial enrollment for PRECISION 1, the Company’s Phase 2 registrational trial
Collaborations
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.